Zymeworks reports $324M cash, provides 2025-2026 pipeline milestones and cash runway into 2H-2027

Zymeworks Inc.

Cash resources ~$324M as of Dec 31, 2024, plus $25M milestone from Jazz expected in Q1 2025.
Cash runway expected to fund planned operations into 2H-2027, including anticipated regulatory milestone payments.
Phase 3 HERIZON-GEA-01 top-line results for zanidatamab in first-line GEA expected 2Q 2025; sBLA later in 2025.
Potential EU approval for zanidatamab in second-line BTC as early as 2Q 2025; China NMPA decision as early as 2H 2025.
IND applications for ZW220, ZW251 in solid tumors in 2025; ZW209 and ZW1528 (AIID) INDs in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.